Home > Press > Zecotek Receives Canadian Patent Allowance For LFS Scintillation Material
Abstract:
Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I) today announced that the Canadian Patent Office has issued Notice of Allowance to Zecotek Imaging Systems Singapore Pte. Ltd., a wholly-owned subsidiary, for its LFS scintillation material. This application is identical to the LFS scintillation applications that have been issued or allowed in the U.S., Russia, China, Europe and Japan.
"Receiving the notice of allowance from the Canadian Patent Office is an important step in protecting our intellectual property and it offers another level of protection for our intellectual property across North America," said Dr. A. F. Zerrouk, Chairman and CEO of Zecotek. "Due to our work with the University of Washington and with leading medical equipment manufacturers, our LFS scintillation material is now widely recognized as an important new material for enhancing the performance of a wide range of imaging devices, and in particular, for its impact with next generation Positron Emission Tomography (PET) medical imaging."
Zecotek has developed and patented a new class of advanced materials targeted at the next-generation of PET, PET-CT and PET-MRI medical imaging scanners. When combined with Zecotek's MAPD solid-state photo detectors, the new scintillation materials allows for medical imaging devices to have higher resolution, enhanced diagnosis, improved patient outcomes, faster patient throughput and lower unit costs.
Other medical applications for LFS are in micro-PET detectors, widely used in drug research, and in gamma cameras used for breast and prostate examinations. Non-medical applications include gamma ray detector systems for homeland security, geological surveying, materials analysis, high energy physics and nuclear stockpile monitoring.
####
About Zecotek Photonics Inc.
Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I) is a photonics technology company developing leading-edge products: crystals, photo detectors, lasers, imaging and 3D display technologies, for medical, biotech, industrial, nanotech and atomic/molecular science applications. Founded in 2003, the company has three distinct operating divisions: imaging, lasers and 3D display and labs located in Canada, the United States, Singapore, Malaysia and Russia. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit www.zecotek.com.
This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
For more information, please click here
Contacts:
Zecotek Photonics Inc.
Product and Technical Information
Susana Mendez Alcala
(604) 827-5232
Email:
or
Caliber Capital & Communications
Investor Information
Tim McNulty
(778) 327-6678
Email:
Copyright © Marketwire
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Imaging
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Tools
Turning up the signal November 8th, 2024
Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024
Faster than one pixel at a time – new imaging method for neutral atomic beam microscopes developed by Swansea researchers August 16th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||